Education
About Us
Working with TipRanks
Follow Us
LABORATORIO REIG JOFRE S.A. (GB:0RB1)
LSE:0RB1
0RB1 Stock Chart & Stats
€2.67
€0.04(1.57%)
At close: 4:00 PM EST
€2.67
€0.04(1.57%)
Day’s Range― - ―
52-Week Range€2.55 - €3.38
Previous CloseN/A
Volume1.25K
Average Volume (3M)286.00
Market Cap
€218.06M
Enterprise Value€270.63M
Total Cash (Recent Filing)€10.84M
Total Debt (Recent Filing)€67.06M
Price to Earnings (P/E)49.2
Beta0.26
Next Earnings
Feb 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding82,219,240
10 Day Avg. Volume278
30 Day Avg. Volume286
Financial Highlights & Ratios
PEG Ratio2.30
Price to Book (P/B)0.93
Price to Sales (P/S)0.59
P/FCF Ratio18.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash GenerationStrong operating cash flow and 66% free-cash-flow growth provide durable funding for R&D, capex and potential acquisitions without heavy reliance on debt. That cash resilience supports long-term pipeline investment, regulatory compliance and flexibility through industry cycles.
Balance Sheet StrengthLow leverage (D/E ~0.27) and a high equity ratio signal conservative capitalization that reduces refinancing and interest-rate risk. This financial stability supports sustained investment in manufacturing capacity and regulatory processes critical for durable pharma operations and growth.
Diversified Revenue ModelA mix of prescription and OTC sales, partnerships, licensing and royalties diversifies cash flow sources and lowers product concentration risk. Structurally this supports steadier revenues, enables access to new markets via alliances, and underpins long-term product pipeline monetization.
Bears Say
EPS DeteriorationA steep EPS decline (~-55%) points to meaningful earnings volatility or one-off charges that weaken core profitability. Persistently depressed EPS can erode reinvestment capacity, constrain capital allocation and reduce financial flexibility over multiple quarters.
Thin Profitability MarginsLow net and operating margins limit the firm's ability to absorb cost inflation or price pressure, reducing free cash available for R&D and expansion. Structurally thin margins make long-term earnings generation sensitive to competitive and input-cost shifts in the pharma sector.
Modest Return On EquityROE near 4.85% indicates modest capital efficiency relative to many pharmaceutical peers. Over time, lower returns can pressure management to pursue higher-risk growth or capital raises, potentially diluting shareholders or increasing strategic execution risk.
LABORATORIO REIG JOFRE News
0RB1 FAQ
What was LABORATORIO REIG JOFRE S.A.’s price range in the past 12 months?
LABORATORIO REIG JOFRE S.A. lowest share price was €2.55 and its highest was €3.38 in the past 12 months.
What is LABORATORIO REIG JOFRE S.A.’s market cap?
LABORATORIO REIG JOFRE S.A.’s market cap is €218.06M.
When is LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date?
LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date is Feb 27, 2026 which is in 7 days.
How were LABORATORIO REIG JOFRE S.A.’s earnings last quarter?
LABORATORIO REIG JOFRE S.A. released its earnings results on Nov 05, 2025. The company reported €0.004 earnings per share for the quarter, beating the consensus estimate of N/A by €0.004.
Is LABORATORIO REIG JOFRE S.A. overvalued?
According to Wall Street analysts LABORATORIO REIG JOFRE S.A.’s price is currently Overvalued.
Does LABORATORIO REIG JOFRE S.A. pay dividends?
LABORATORIO REIG JOFRE S.A. does not currently pay dividends.
What is LABORATORIO REIG JOFRE S.A.’s EPS estimate?
LABORATORIO REIG JOFRE S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE S.A. have?
LABORATORIO REIG JOFRE S.A. has 82,219,240 shares outstanding.
What happened to LABORATORIO REIG JOFRE S.A.’s price movement after its last earnings report?
LABORATORIO REIG JOFRE S.A. reported an EPS of €0.004 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.413%.
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE S.A.?
Currently, no hedge funds are holding shares in GB:0RB1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LABORATORIO REIG JOFRE S.A.
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan Despí, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.
Technical Analysis
Almirall
―
Faes Farma
―
Laboratorios Farmaceuticos Rovi
―
Oryzon Genomics SA
―
Atrys Health SA
―
Options Prices
Currently, No data available
---